| Year |
Citation |
Score |
| 2023 |
Müller N, Lorenz C, Ostendorp J, Heisel FS, Friese UP, Cartolano M, Plenker D, Tumbrink HL, Heimsoeth A, Baedeker P, Ortiz-Cuaran S, Weiss J, Büttner R, Peifer M, Thomas RK, ... Sos ML, et al. Characterizing evolutionary dynamics reveals strategies to exhaust the spectrum of subclonal resistance in EGFR-mutant lung cancer. Cancer Research. PMID 37289018 DOI: 10.1158/0008-5472.CAN-22-2605 |
0.334 |
|
| 2022 |
Riedel R, Fassunke J, Tumbrink HL, Scheel AH, Heydt C, Hieggelke L, Scheffler M, Heimsoeth A, Nogova L, Michels S, Weber JP, Fischer RN, Eisert A, Westphal T, Schaufler D, ... ... Sos ML, et al. Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors. European Journal of Cancer (Oxford, England : 1990). 179: 124-135. PMID 36521334 DOI: 10.1016/j.ejca.2022.11.010 |
0.348 |
|
| 2022 |
Lategahn J, Tumbrink HL, Schultz-Fademrecht C, Heimsoeth A, Werr L, Niggenaber J, Keul M, Parmaksiz F, Baumann M, Menninger S, Zent E, Landel I, Weisner J, Jeyakumar K, Heyden L, ... ... Sos ML, et al. Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. Journal of Medicinal Chemistry. PMID 35486541 DOI: 10.1021/acs.jmedchem.1c02080 |
0.63 |
|
| 2022 |
Werr L, Plenker D, Dammert MA, Lorenz C, Brägelmann J, Tumbrink HL, Klein S, Schmitt A, Büttner R, Persigehl T, Shokat KM, Wunderlich FT, Schram AM, Peifer M, Sos ML, et al. CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization. Molecular Cancer Therapeutics. PMID 35247925 DOI: 10.1158/1535-7163.MCT-21-0820 |
0.45 |
|
| 2021 |
Schaufler D, Ast DF, Tumbrink HL, Abedpour N, Maas L, Schwäbe AE, Spille I, Lennartz S, Fassunke J, Aldea M, Besse B, Planchard D, Nogova L, Michels S, Kobe C, ... ... Sos ML, et al. Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. Npj Precision Oncology. 5: 102. PMID 34921211 DOI: 10.1038/s41698-021-00241-9 |
0.423 |
|
| 2021 |
Brägelmann J, Lorenz C, Borchmann S, Nishii K, Wegner J, Meder L, Ostendorp J, Ast DF, Heimsoeth A, Nakasuka T, Hirabae A, Okawa S, Dammert MA, Plenker D, Klein S, ... ... Sos ML, et al. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nature Communications. 12: 5505. PMID 34535668 DOI: 10.1038/s41467-021-25728-8 |
0.402 |
|
| 2021 |
Bebber CM, Thomas ES, Stroh J, Chen Z, Androulidaki A, Schmitt A, Höhne MN, Stüker L, de Pádua Alves C, Khonsari A, Dammert MA, Parmaksiz F, Tumbrink HL, Beleggia F, Sos ML, et al. Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nature Communications. 12: 2048. PMID 33824345 DOI: 10.1038/s41467-021-22336-4 |
0.332 |
|
| 2020 |
Tumbrink HL, Heimsoeth A, Sos ML. The next tier of EGFR resistance mutations in lung cancer. Oncogene. PMID 33060857 DOI: 10.1038/s41388-020-01510-w |
0.405 |
|
| 2020 |
Nogova L, Mattonet C, Scheffler M, Taubert M, Gardizi M, Sos ML, Michels S, Fischer RN, Limburg M, Abdulla DSY, Persigehl T, Kobe C, Merkelbach-Bruse S, Franklin J, Backes H, et al. Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. Cancer Medicine. PMID 32436621 DOI: 10.1002/cam4.3131 |
0.322 |
|
| 2019 |
Michels S, Heydt C, van Veggel B, Deschler-Baier B, Pardo N, Monkhorst K, Rüsseler V, Stratmann J, Griesinger F, Steinhauser S, Kostenko A, Diebold J, Fassunke J, Fischer R, Engel-Riedel W, ... ... Sos ML, et al. Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Jco Precision Oncology. 3. PMID 32914023 DOI: 10.1200/PO.18.00210 |
0.385 |
|
| 2019 |
Fassunke J, Heydt C, Michels S, Van Veggel B, Müller F, Keul M, Dammert MA, Schmitt A, Smit EF, Kast S, Wolf J, Buettner R, Sos ML, Rauh D, Merkelbach-Bruse S. New insights into acquired resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor therapy in lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii51. PMID 32131274 DOI: 10.1093/Annonc/Mdz063.030 |
0.634 |
|
| 2019 |
Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, ... ... Sos ML, et al. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications. 10: 3485. PMID 31375684 DOI: 10.1038/S41467-019-11371-X |
0.344 |
|
| 2019 |
Sos ML, Tumbrink HL, Schultz-Fademrecht C, Lategahn J, Keul M, Niggenaber J, Heimsoeth A, Baumann M, Werr LH, Degenhart C, Menninger S, Heuckmann JM, Thomas RK, Rauh D, Klebl B. Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001. Journal of Clinical Oncology. 37: e14718-e14718. DOI: 10.1200/Jco.2019.37.15_Suppl.E14718 |
0.663 |
|
| 2019 |
Riedel R, Heydt C, Scheel AH, Tumbrink HL, Brägelmann J, Castiglione R, Nogova L, Abdulla DS, Michels SYF, Scheffler M, Fischer RN, Koleczko S, Merkelbach-Bruse S, Sos M, Büttner R, et al. Acquired resistance to MET inhibition in MET driven NSCLC. Journal of Clinical Oncology. 37: 9030-9030. DOI: 10.1200/Jco.2019.37.15_Suppl.9030 |
0.476 |
|
| 2018 |
Scheffler M, Ihle MA, Hein R, Merkelbach-Bruse S, Scheel AH, Siemanowski J, Brägelmann J, Kron A, Abedpour N, Ueckeroth F, Schüller M, Koleczko S, Michels S, Fassunke J, Pasternack H, ... ... Sos ML, et al. K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30605727 DOI: 10.1016/j.jtho.2018.12.013 |
0.32 |
|
| 2018 |
Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, ... ... Sos ML, et al. Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications. 9: 4655. PMID 30405134 DOI: 10.1038/S41467-018-07078-0 |
0.63 |
|
| 2018 |
Mollaoglu G, Guthrie MR, Bohm S, Bragelmann J, Chalishazar MD, Ireland AS, Huang F, Hu Z, Cardnell RJ, Sen T, Gertz J, Johnson JE, Gazdar AF, Byers LA, DeBerardinis RJ, ... ... Sos M, et al. Abstract IA27: MYC drives molecular and therapeutically distinct subtype of SCLC Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Aacriaslc18-Ia27 |
0.434 |
|
| 2017 |
Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, ... ... Sos ML, et al. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports. 20: 2833-2845. PMID 28930680 DOI: 10.1016/J.Celrep.2017.08.082 |
0.613 |
|
| 2017 |
Brägelmann J, Böhm S, Guthrie MR, Mollaoglu G, Oliver TG, Sos ML. Family matters: how MYC family oncogenes impact small cell lung cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 28737478 DOI: 10.1080/15384101.2017.1339849 |
0.361 |
|
| 2017 |
Malchers F, Ercanoglu MS, Schütte D, Castiglione R, Tischler V, Michels S, Dahmen I, Brägelmann J, Menon R, Heuckmann JM, George J, Ansén S, Sos ML, Soltermann A, Peifer M, et al. Mechanisms of primary drug resistance in FGFR1 amplified lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28630215 DOI: 10.1158/1078-0432.CCR-17-0478 |
0.407 |
|
| 2017 |
Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, ... ... Sos ML, et al. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Science Translational Medicine. 9. PMID 28615362 DOI: 10.1126/Scitranslmed.Aah6144 |
0.558 |
|
| 2016 |
Mollaoglu G, Guthrie MR, Böhm S, Brägelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Vahrenkamp JM, ... ... Sos ML, et al. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell. PMID 28089889 DOI: 10.1016/J.Ccell.2016.12.005 |
0.363 |
|
| 2016 |
Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen I, Scheel A, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, ... ... Sos ML, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27252416 DOI: 10.1158/1078-0432.Ccr-15-1915 |
0.347 |
|
| 2015 |
Costa HA, Leitner MG, Sos ML, Mavrantoni A, Rychkova A, Johnson JR, Newton BW, Yee MC, De La Vega FM, Ford JM, Krogan NJ, Shokat KM, Oliver D, Halaszovich CR, Bustamante CD. Discovery and functional characterization of a neomorphic PTEN mutation. Proceedings of the National Academy of Sciences of the United States of America. 112: 13976-81. PMID 26504226 DOI: 10.1073/Pnas.1422504112 |
0.573 |
|
| 2015 |
Engel J, Richters A, Getlik M, Tomassi S, Keul M, Termathe M, Lategahn J, Becker C, Mayer-Wrangowski S, Grütter C, Uhlenbrock N, Krüll J, Schaumann N, Eppmann S, Kibies P, ... ... Sos ML, et al. Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. Journal of Medicinal Chemistry. 58: 6844-63. PMID 26275028 DOI: 10.1021/Acs.Jmedchem.5B01082 |
0.631 |
|
| 2015 |
Scheffler M, Merkelbach-Bruse S, Bos M, Fassunke J, Gardizi M, Michels S, Groneck L, Schultheis AM, Malchers F, Leenders F, Kobe C, König K, Heukamp LC, Sos ML, Thomas RK, et al. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: e40-3. PMID 26001148 DOI: 10.1097/JTO.0000000000000503 |
0.42 |
|
| 2014 |
Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Reports. 8: 1037-48. PMID 25127139 DOI: 10.1016/J.Celrep.2014.07.010 |
0.761 |
|
| 2014 |
Scheffler M, Gardizi M, Bos MCA, Nogova L, Michels S, Persigehl T, Sos ML, Dietlein F, Zander T, Wolf J. BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. Journal of Clinical Oncology. 32: TPS2645-TPS2645. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps2645 |
0.353 |
|
| 2014 |
Sos M, Levin R, Gordan J, Oses-Prieto J, Webber J, Salt M, Hann B, Burlingame A, McCormick F, Bandyopadhyay S, Shokat K. 73 Differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer European Journal of Cancer. 50: 28-29. DOI: 10.1016/S0959-8049(14)70199-6 |
0.741 |
|
| 2013 |
Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 503: 548-51. PMID 24256730 DOI: 10.1038/Nature12796 |
0.687 |
|
| 2013 |
Lopez MS, Choy JW, Peters U, Sos ML, Morgan DO, Shokat KM. Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technology. Journal of the American Chemical Society. 135: 18153-9. PMID 24171479 DOI: 10.1021/Ja408704U |
0.749 |
|
| 2013 |
Hertz NT, Berthet A, Sos ML, Thorn KS, Burlingame AL, Nakamura K, Shokat KM. A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1. Cell. 154: 737-47. PMID 23953109 DOI: 10.1016/J.Cell.2013.07.030 |
0.71 |
|
| 2013 |
Richters A, Ketzer J, Getlik M, Grütter C, Schneider R, Heuckmann JM, Heynck S, Sos ML, Gupta A, Unger A, Schultz-Fademrecht C, Thomas RK, Bauer S, Rauh D. Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design. Journal of Medicinal Chemistry. 56: 5757-72. PMID 23773153 DOI: 10.1021/Jm4004076 |
0.619 |
|
| 2013 |
Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, ... ... Sos ML, et al. Characteristics of lung cancers harboring NRAS mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2584-91. PMID 23515407 DOI: 10.1158/1078-0432.Ccr-12-3173 |
0.324 |
|
| 2012 |
Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, Müller C, Koker M, Richters A, Heynck S, Malchers F, Heuckmann JM, Seidel D, Eyers PA, Ullrich RT, Antonchick AP, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 17034-9. PMID 23035247 DOI: 10.1073/Pnas.1207310109 |
0.642 |
|
| 2012 |
Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics. 44: 1104-10. PMID 22941188 DOI: 10.1038/Ng.2396 |
0.588 |
|
| 2012 |
Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4682-90. PMID 22912387 DOI: 10.1158/1078-0432.Ccr-11-3260 |
0.363 |
|
| 2012 |
Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ansén S, Engel-Riedel W, Brockmann M, Serke M, ... ... Sos M, et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 1473-80. PMID 22684217 DOI: 10.1038/Modpathol.2012.102 |
0.387 |
|
| 2012 |
Sos ML, Thomas RK. Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene. 31: 4811-4. PMID 22266863 DOI: 10.1038/onc.2011.640 |
0.367 |
|
| 2012 |
Scheffler M, Bos MCA, Sos M, Nogova L, Mattonet C, Papachristou I, Kahraman D, Kobe C, Boellaard R, Lammertsma AA, Heukamp LC, Büttner R, Elter T, Toepelt K, Engel-Riedel W, et al. MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. Journal of Clinical Oncology. 30: 7603-7603. DOI: 10.1200/Jco.2012.30.15_Suppl.7603 |
0.311 |
|
| 2012 |
Ohashi K, Sequist LV, Sos M, Chen X, Rudin CM, Moran T, Arcila ME, Lovly CM, Vnencak-Jones CL, Sasaki H, Dias-Santagata D, Dubinett SM, Riely GJ, Ladanyi M, Franklin WA, et al. Characteristics of NSCLCs harboring NRAS mutations. Journal of Clinical Oncology. 30: 7532-7532. DOI: 10.1200/Jco.2012.30.15_Suppl.7532 |
0.457 |
|
| 2011 |
Nogova L, Mattonet C, Scheffler M, Papachristou I, Muthen N, Sos M, Hacker UT, Elter T, Backes H, Kobe C, Rhiem K, Mallmann P, Fuhr U, Schnell R, Katay I, et al. The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13613. PMID 28023553 DOI: 10.1200/Jco.2011.29.15_Suppl.E13613 |
0.403 |
|
| 2011 |
Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery. 1: 78-89. PMID 22328973 DOI: 10.1158/2159-8274.Cd-11-0005 |
0.651 |
|
| 2011 |
Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown TJ, et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine. 17: 1504-8. PMID 21983857 DOI: 10.1038/Nm.2473 |
0.312 |
|
| 2011 |
Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7394-401. PMID 21948233 DOI: 10.1158/1078-0432.Ccr-11-1648 |
0.627 |
|
| 2011 |
Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science Translational Medicine. 3: 90ra59. PMID 21734175 DOI: 10.1126/Scitranslmed.3002356 |
0.405 |
|
| 2011 |
Rode HB, Sos ML, Grütter C, Heynck S, Simard JR, Rauh D. Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorganic & Medicinal Chemistry. 19: 429-39. PMID 21130659 DOI: 10.1016/J.Bmc.2010.11.007 |
0.57 |
|
| 2011 |
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer (Science Translational Medicine (2011) 3) Science Translational Medicine. 3. DOI: 10.1126/scitranslmed.3002121 |
0.549 |
|
| 2010 |
Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine. 2: 62ra93. PMID 21160078 DOI: 10.1126/Scitranslmed.3001451 |
0.609 |
|
| 2010 |
Pawar VG, Sos ML, Rode HB, Rabiller M, Heynck S, van Otterlo WA, Thomas RK, Rauh D. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. Journal of Medicinal Chemistry. 53: 2892-901. PMID 20222733 DOI: 10.1021/Jm901877J |
0.646 |
|
| 2010 |
Peifer M, Weiss J, Sos ML, Koker M, Heynck S, Netzer C, Fischer S, Rode H, Rauh D, Rahnenführer J, Thomas RK. Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. Plos One. 5: e8919. PMID 20111714 DOI: 10.1371/Journal.Pone.0008919 |
0.564 |
|
| 2010 |
Sos ML, Rode HB, Heynck S, Peifer M, Fischer F, Klüter S, Pawar VG, Reuter C, Heuckmann JM, Weiss J, Ruddigkeit L, Rabiller M, Koker M, Simard JR, Getlik M, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research. 70: 868-74. PMID 20103621 DOI: 10.1158/0008-5472.Can-09-3106 |
0.663 |
|
| 2009 |
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462: 108-12. PMID 19847166 DOI: 10.1038/Nature08460 |
0.381 |
|
| 2009 |
Sos ML, Thomas RK. Systematically linking drug susceptibility to cancer genome aberrations. Cell Cycle (Georgetown, Tex.). 8: 3652-6. PMID 19844167 DOI: 10.4161/cc.8.22.9936 |
0.317 |
|
| 2009 |
Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America. 106: 18351-6. PMID 19805051 DOI: 10.1073/Pnas.0907325106 |
0.702 |
|
| 2009 |
Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M, Li D, Ullrich R, Koker M, Fischer F, Shimamura T, Rauh D, Mermel C, Fischer S, Stückrath I, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. The Journal of Clinical Investigation. 119: 1727-40. PMID 19451690 DOI: 10.1172/Jci37127 |
0.625 |
|
| 2009 |
Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research. 69: 3256-61. PMID 19351834 DOI: 10.1158/0008-5472.Can-08-4055 |
0.405 |
|
| 2008 |
Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, Borgman CL, Tawadros S, Li H, Sos ML, Backes H, Shapiro GI, Wolf J, Jacobs AH, Thomas RK, et al. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). Plos One. 3: e3908. PMID 19079597 DOI: 10.1371/Journal.Pone.0003908 |
0.348 |
|
| 2008 |
Sos ML, Zander T, Thomas RK, Staratschek-Jox A, Claasen J, Wolf J. Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 170-3. PMID 18303439 DOI: 10.1097/JTO.0b013e3181622c05 |
0.412 |
|
| Show low-probability matches. |